Skyscape Web Viewer : Radiation Oncology Question Review : Main Index

View All
Paranasal sinus anticipated 5-yr LRC and OS neuroendocrine differentiation staging system for esthesioneuroblastoma effect of orbital involvement Ohngren's line and Vidian canal subclinical nodal involvement
PCI
Pediatric gliomas high-grade second malignancy, risk of genetic syndrome histologic subtypes treatment approach
Pediatric leukemia cranial irradiation prognostic features of ALL pediatric ALL and AML prognostic features of AML
Penile cancer median survival rate preservation rate for a T1-t3 risk factors staging potential critical pre-radiation anatomic factor prognostic factor risk of nodal disease T2
Phenytoin Answer 2.105 Question 2.105
Pilocytic astrocytomas histopathologic feature for vs nonpilocytic tumors surgery and radiation in
Pituitary tumors nonfunctional pituitary adenomas recommended SRS doses side effect of external-beam radiation treatment treatment modality fractionated radiation therapy pituitary adenoma-induced acromegaly secretory type SRS vs radiation therapy
post-mastectomy radiation therapy (PMRT)
Postoperative radiotherapy indications and evidence altered fractionation postoperative dose
primary CNS lymphoma CHOD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) chemotherapy methotrexate-based chemotherapy RPA classification median survival with radiation risk factors treatment
prophylactic cranial irradiation (PCI) Answer 4.77 Answer 4.79 Answer 4.81 Answer 4.83 Answer 4.78 Answer 4.80 Answer 4.82 Answer 4.84 survival rate Answer 4.85
Pancreatic cancer
PMRT
Prostate cancer-adjuvant and salvage radiation benefits hormone treatments with predictors of biochemical outcome survival rate dose regime used for median PSA sites of recurrence s/p prostatectomy SWOG trials
Prostate cancer-branchytherapy as monotherapy dose constraints half-life of I-125 and Pd-103 PSA rise, significance of disease-specific outcomes in exclusion criteria outcome between I-125 and Pd-103 with EBRT
Prostate cancer-general AUA scores, role in in regional lymph node nodal staging Prostate Cancer Prevention Trial (PCPT) trial Roach equations, reliability of half-life of prostate specific antigen (PSA) M-staging for adenocarcinoma of prognostic parameters prostate specific antigen (PSA), screening of stage migration of
Prostate cancer-high risk and rogen deprivation, effects of bony metastasis in PSA follow-up post radiation testosterone production in normal male ASCENDE-RT trial EBRT, outcome with radiation therapy
Prostate cancer-low risk doses for radiation therapy Epstein criteria moderate hypofractionation for Pollack dose escalation phase III study support treatment Zietman PROG 95-009 phase III study biochemical failure risks DVH and dosimetric plan, constraints with IMRT on active surveillance RTOG 0126 treatment
Prostate cancer-node-positive and rogen deprivation therapy and rogen deprivation in radiation during radical prostatectomy

NDX